GWGuoqin Wang

Guoqin Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Guoqin Wang has a total of 9 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Meta-Analysis of Randomized Controlled Trials Assessing the Efficacy and Safety of Endothelin Receptor Antagonists in CKD

    by Yunqi Shi, Nan Ye, Guoqin Wang, Hong Cheng

    Key Points: Endothelin receptor antagonists should be applied for patients with CKD whose proteinuria and high risk of kidney function decline remains insufficiently controlled. We recommend that endothelin A receptor-selective endothelin receptor antagonists should be preferable for patients with CKD with consideration for combination therapy with sodium-glucose cotransporter-2 inhibitors. Background: Endothelin receptor antagonists (ERAs) are considered a potential effective treatment to reduce proteinuria and protect kidney function for patients with CKD; however, they may cause fluid retention. We conducted this meta-analysis to quantify the efficacy and safety of ERAs in CKD. Methods: We searched Cochrane Library, Ovid Medline, and Ovid Embase for randomized controlled trials up to January 2025. Continuous and dichotomous data were reported as standardized mean differences (SMDs) with 95% confidence intervals (CIs) and risk ratios (RRs) with 95% CIs, respectively. Results: Fourteen trials enrolling 6412 patients were included. Compared with the control group, ERAs decreased the risk of ESKD (RR=0.76, 95% CI [0.61 to 0.96]), reduced the urine protein-to-creatinine ratio (SMD=−0.56, 95% CI [−0.78 to −0.35]) and urine albumin-to-creatinine ratio (SMD=−0.64, 95% CI [−0.75 to −0.53]), achieved more frequent complete proteinuria remission (RR=2.61, 95% CI [1.84 to 3.71]) and partial proteinuria remission (RR=1.51, 95% CI [1.32 to 1.73]), slowed the decline of eGFR in the subgroup with a follow-up duration of at least 1 year (SMD=0.18, 95% CI [0.04 to 0.32]), improved the chronic eGFR slope (SMD=0.15, 95% CI [0.01 to 0.30]), and decreased systolic BP (SMD=−0.53, 95% CI [−0.76 to −0.30]) and diastolic BP (SMD=−0.78, 95% CI [−1.18 to −0.38]). Although the risk was increased in B-type natriuretic peptide (SMD=0.08, 95% CI [0.01 to 0.16]) and body weight (SMD=0.15, 95% CI [0.01 to 0.29]), ERAs did not increase the incidence of edema, fluid retention, or heart failure. The risk of hypotension was higher with ERAs compared with the control group (RR=1.92, 95% CI [1.36 to 2.70]). Conclusion: These findings suggest that ERAs may reduce proteinuria, prevent kidney disease progression, and lower BP in individuals with CKD.


  • Open Access

    Analysis of Cardiovascular and Cerebrovascular Prognosis and Risk Factors in Patients with Primary Membranous Nephropathy

    by Nan Ye, Lei Yang, Guoqin Wang, Wenrong Cheng, Bing Xie, Hongrui Dong, Lingqiang Kong, Xiaoyi Zhao, Yanqiu Geng, Hong Cheng

    Key Points: Higher serum phospholipase A2 receptor antibody is an independent risk factor of arterial and venous thromboembolic events in patients with primary membranous nephropathy. The inflammatory system may play a role in this relationship. Background: This study investigated risk factors and possible mechanisms of arterial and venous thromboembolic events in patients with primary membranous nephropathy (pMN). Methods: Patients with pMN confirmed by renal biopsy from June 1, 2010, to March 3, 2023, were included, and the study outcome was set as a composite end point of acute coronary syndrome, heart failure, cerebral infarction, arrhythmia, pulmonary embolism, deep venous thrombosis, and all-cause mortality. Results: A total of 433 pMN patients with complete data were included, with a median follow-up time of 73 (45.5–101.6) months and a composite end point rate of 10.2%. We divided all patients with events into an early event group (events occurring in the first 2 years after renal biopsy) and a late event group (events occurring after 2 years after renal biopsy) according to the time of event. It showed a lower serum albumin and higher baseline value of serum phospholipase A2 receptor (PLA2R) antibody titer and mean value of each follow-up in the early event group compared with the late event group. Cox proportional hazards model showed that after adjusting for confounding factors, in addition to older age, history of deep vein thrombosis and higher urinary protein, higher baseline serum PLA2R antibody titers (odds ratio [OR], 1.034; 95% confidence interval [CI], 1.006 to 1.063; P = 0.015), and high high-sensitivity C-reactive protein level (OR, 1.049; 95% CI, 1.002 to 1.098; P = 0.041), renal pathology with segmental sclerotic lesions (OR, 3.480; 95% CI, 1.338 to 9.050; P = 0.011) were also independent risk factors for the occurrence of end point events. The results also showed that baseline serum IL-6 levels were significantly higher in the event group compared with the nonevent group (4.25 versus 3.21 pg/ml), and the difference was statistically significant (P = 0.009). Conclusions: In the early event group, higher serum PLA2R antibody and renal pathology with segmental sclerosis lesions may affect the occurrence of cardiovascular, cerebrovascular, and venous thrombotic events. The inflammatory system may play a role in this relationship.